Myths vs facts: FADS1 and menopause

FADS1 encodes delta-5 desaturase, a key enzyme in polyunsaturated fatty acid (PUFA) metabolism, converting alpha-linolenic acid (ALA) to EPA and DHA. During menopause, declining estrogen levels alter lipid metabolism and inflammatory responses. Some consumer DNA tests claim that specific FADS1 variants (e.g., rs174547) are linked to more severe hot flashes or a higher need for omega-3s. The evidence, however, is primarily at the GWAS level—associations are statistically significant but have small effect sizes and are ancestry-dependent. No robust clinical trials have validated that personalized omega-3 supplementation based on FADS1 genotype improves menopausal symptoms. Fact: adequate omega-3 intake may support anti-inflammatory pathways in some women, but the benefit is not genotype-specific. Myths arise from overinterpreting weak genetic signals. Consumers should not use such test results to guide medical decisions. For menopause management, evidence-based strategies like diet, exercise, and professional medical advice remain far more impactful than a single genetic variant.